The healthtech industry is experiencing intense competition as companies race to develop software and artificial intelligence (AI) tools for clinical decision support, medical telemetry, robotic surgery, surgical navigation, medical imaging analysis, drug discovery, clinical trial management, and countless other medical applications. This competitive landscape is driving substantial investment and rapid innovation, with established medtech providers
With artificial intelligence tools becoming part of everyday decision-making, for some, chatbots are a first stop for help with answering questions, including questions that feel “legal” in nature. Such questions might include whether a contract clause is enforceable, how to respond to a demand letter, or what to say in an internal investigation. The AI
After years of resistance from the United States Patent and Trademark Office (USPTO) toward AI patent applications, the patent outlook for AI-related inventions in 2026 appears to be promising thanks to recent changes at the USPTO under Director John A. Squires.
On Sept. 22, 2025, the USPTO swore in Squires as its 60th director. Since
| Go-To Guide: |
| California has enacted multiple AI regulations, including new laws on AI safety and whistleblowers, training-data transparency and watermarking, HR and ADS anti-discrimination rules, and prohibitions on anticompetitive “common pricing algorithms.”New York, building on NYC Local Law 144, has passed several AI-related bills including the RAISE Act, social-media warning requirements, synthetic-performer disclosures, expanded publicity |
On Dec. 11, 2025, President Trump signed an executive order titled “Ensuring a National Policy Framework for Artificial Intelligence” that seeks to establish federal supremacy over state AI regulation. The order states that the Administration is concerned that some state-level regulation of AI may be overly burdensome, ideologically biased, or counterproductive to U.S. AI leadership
